Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afuresertib + sintilimab + docetaxel
- Development stage
- Unknown
- Lead developer
- Laekna
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**afuresertib + sintilimab + docetaxel** is a combination therapy under clinical investigation for the treatment of solid tumors resistant to prior anti-PD-1/PD-L1 therapy, including non-small cell lung cancer (NSCLC), gastric cancer/gastroesophageal junction cancer, esophageal cancer, cervical cancer, and endometrial cancer. - **Afuresertib** is an orally available, selective small molecule inhibitor of AKT, a kinase in the PI3K/AKT pathway involved in cell survival and proliferation. - **Sintilimab** is a human IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, acting as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor responses. - **Docetaxel** is a cytotoxic chemotherapy agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. The combination aims to overcome resistance to immune checkpoint blockade by combining immunotherapy with pathway inhibition and cytotoxic chemotherapy. Early-phase clinical trials are underway, jointly developed by Innovent and Laekna, to determine safety, recommended dosing, and preliminary efficacy in selected cancers[1][4][6][7].
- Brand names
- Tyvyt (sintilimab)Taxotere (docetaxel)
- Other names
- afuresertib + sintilimab + docetaxel
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on afuresertib + sintilimab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afuresertib + sintilimab + docetaxel.